Our Advantages

Excellent Safety Profile1, 2

Excellent Safety Profile

Sebacia is Safe - affecting only the skin on your face rather than your entire body.1, 2

Targets the Cause of Acne

Targets the Causes of Acne

Selective, localized treatment of the sebaceous gland.

Innovative and New

Innovative and New

Sebacia is the NEW acne treatment that locally targets the main source of acne - the oil! Clearing skin from the inside out!

No Pills or Anesthesia

No Pills or Anesthesia

Three 30-45-minute treatments over two weeks in your dermatologist’s office.



The Sebacia treatment is a NEW acne treatment that combines gold microparticles and laser light to reduce the oil production in the Sebaceous gland.

Simplify Daily Routine

Simplifies Daily Routine

Most treatments for acne require a daily, ongoing routine. Sebacia is more convenient because it is provided in your dermatologist’s office — and there’s often nothing to keep up with at home.

Results up to 24 Months3

Results up to 24 months

Results have been shown to last up to 24 months for most patients using Sebacia.3

No Downtime

No Down Time

The most common side effect Sebacia has is redness after the treatment but that usually goes away between 30 minutes and an hour. There is no downtime from work or school.


1 US FDA 510(k) clinical summary (k181518).

2 Paithankar et al. 2015. Acne Treatment Based on Selective Photothermolysis of Sebaceous Follicles with Topically Delivered Light-Absorbing Gold Microparticles. Journal of Investigational Dermatology, July 2015. 135 (7): pgs. 1727-1734.

3 The US clinical study ended at 12 weeks and demonstrated non-inferiority to laser alone with Sebacia’s last treatment at 2 weeks and laser alone last treatment at 10 weeks, Sebacia’s treatment required significantly fewer laser treatment sessions and significantly lower laser fluence compared to laser alone.
In a non-randomized registry study in Europe, the average improvement in acne lesions at 24 months was 92% (77% free of acne medications, 9% used topicals and 14% used systemics at 24 months).